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Simple Summary: Pyruvate kinase muscle type (PKM) is a key enzyme in glycolysis and is a
mediator of the Warburg effect in tumors. The association of PKM with survival of cancer patients is
controversial. In this study, we investigated the associations of the alternatively spliced transcripts
of PKM with cancer patients’ survival outcomes and explained the conflicts in previous studies.
We discovered three poorly studied alternatively spliced PKM transcripts that exhibited opposite
prognostic indications in different human cancers based on integrative systems analysis. We also
detected their protein products and explored their potential biological functions based on in-vitro
experiments. Our analysis demonstrated that alternatively spliced transcripts of not only PKM
but also other genes should be considered in cancer studies, since it may enable the discovery and
targeting of the right protein product for development of the efficient treatment strategies.
Abstract: Pyruvate kinase muscle type (PKM) is a key enzyme in glycolysis and plays an important
oncological role in cancer. However, the association of PKM expression and the survival outcome
of patients with different cancers is controversial. We employed systems biology methods to reveal
prognostic value and potential biological functions of PKM transcripts in different human cancers.
Protein products of transcripts were shown and detected by western blot and mass spectrometry
analysis. We focused on different transcripts of PKM and investigated the associations between their
mRNA expression and the clinical survival of the patients in 25 different cancers. We find that the
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transcripts encoding PKM2 and three previously unstudied transcripts, namely ENST00000389093,
ENST00000568883, and ENST00000561609, exhibited opposite prognostic indications in different
cancers. Moreover, we validated the prognostic effect of these transcripts in an independent kidney
cancer cohort. Finally, we revealed that ENST00000389093 and ENST00000568883 possess pyruvate
kinase enzymatic activity and may have functional roles in metabolism, cell invasion, and hypoxia
response in cancer cells. Our study provided a potential explanation to the controversial prognos-
tic indication of PKM, and could invoke future studies focusing on revealing the biological and
oncological roles of these alternative spliced variants of PKM.
Keywords: alternative splicing; cancer; PKM; transcriptomics
1. Introduction
Pyruvate kinase muscle type (PKM) is the most-studied isoform of pyruvate kinase
and catalyzes the final step in glycolysis [1]. It is one of the key mediators of the Warburg
effect and plays a pivotal role in controlling tumor metabolism. It has been reported that
the mRNA and protein expression of PKM is strongly associated with the survival of
cancer patients, but the direction of the correlation was contradictory since both activation
and inhibition of this enzyme have been suggested for effective treatment of the cancer
patients [2]. In the Human Pathology Atlas [3], high expression of PKM is significantly
(log-rank p-value < 0.05) associated with the unfavorable prognoses in liver hepatocellular
carcinoma (LIHC), pancreatic adenocarcinoma (PAAD), head and neck squamous cell
carcinoma (HNSC), and lung adenocarcinoma (LUAD), whereas it is also associated with
favorable prognoses in kidney renal clear-cell carcinoma (KIRC), skin cutaneous melanoma
(SKCM), stomach adenocarcinoma (STAD), and thyroid carcinoma (THCA). Thus, mRNA
expression of PKM has ambiguous indication of patients’ survival in different cancer types.
The oncological roles of differentially spliced transcripts of PKM including PKM1
and PKM2, which are mutually exclusive exons 9 and 10 [4], have been previously inves-
tigated. PKM1 constitutively exists as the active tetramer to generate adenosine triphos-
phate (ATP) to supply cellular energy. However, PKM2 can exist as tetramer or dimer,
and the tetramer form is allosterically activated by the glycolytic metabolite fructose-1,6-
biphosphate (FBP) [5,6]. FBP tightly binds to tetrameric PKM2 [7] and the release of FBP
causes PKM2 to switch from tetramer to dimer [8]. Tetrameric PKM2 exhibits high catalytic
activity, which is associated with ATP synthesis and catabolic metabolism [9], while dimeric
PKM2 has low catalytic activity and is the less active state of PKM2.
PKM2 activity is also regulated by post-translational modification such as phospho-
rylation [10–13], acetylation [14,15], oxidation [16], and sumoylation [17], which promote
aerobic glycolysis or tumorigenesis. In addition, nuclear PKM2 also can work as a tran-
scriptional regulator to activate HIF-1α [18], β-catenin [11,19], MEK5 [20], and Oct-4 [21],
which promotes cell proliferation and tumor development. It has been reported that over-
expression of PKM1/2 isoforms promotes tumorigenesis or induces poor prognoses of
patients in multiple cancers [19,22–33] whereas PKM1 expression in place of PKM2 inhibits
tumor cell proliferation [34,35]. Moreover, it has been reported that methylation or deletion
of PKM2 promotes tumor progression in liver cancer, breast cancer, and medulloblas-
toma [36–39]. Therefore, the function of alternative splicing products of PKM in tumor
oncogenesis and progression remains controversial.
Due to alternative splicing, there are 14 known isoforms of the PKM, of which PKM1
and PKM2 are well studied isoforms. To our knowledge, the roles of other protein products
of PKM apart from PKM1 and PKM2 have not been studied. In this study, we focused on
14 different transcripts of PKM and systematically investigated the biological functions
of each transcript as well as their association with the clinical outcomes in 25 different
cancer types.
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2. Results
2.1. The Alternatively Spliced Protein Coding Transcripts of Pyruvate Kinase Muscle Type (PKM)
PKM is composed of 12 exons according to the reference genome Ensembl Ver-
sion 83 (GENCODE Version 24; Figure 1a; Table S1). Both of the two commonly stud-
ied transcripts of PKM, ENST00000319622 (encoding PKM1) and ENST00000335181 (en-
coding PKM2), are composed by 11 exons where 10 of them are shared. The most
important difference between PKM1 and PKM2 is their specificity on exon 9 and 10,
where PKM1 includes the former and PKM2 includes the latter. In addition to the
transcripts of PKM1 and PKM2, there are another 12 known transcripts of PKM and
with different lengths of nucleotide sequences and exon combinations. As shown in
Figure 1a, ENST00000561609 (PKM-609), ENST00000568883 (PKM-883), ENST00000565184,
ENST00000565154, and ENST00000568459 are composed of different subsequences from
PKM1, as well as ENST00000389093 (PKM-093) and ENST00000449901 are composed of
different subsequences from PKM2. ENST00000564178 has its special translated region in
exon E1. The other transcripts are very short subsequences of PKM1/PKM2.
Next, we retrieved mRNA expression of these 14 transcripts in 25 different cancer types
in The Cancer Genome Atlas (TCGA; Table S2). As shown in Figure 1b, we found that seven
transcripts had mRNA expression (average TPM) > 5 in at least one cancer type, including
PKM1, PKM2, PKM-093, PKM-609, PKM-883, ENST00000562997, and ENST00000568459.
Among them, PKM2 shows the highest expression level in all the cancer types followed by
PKM-093 and PKM-883, and it represents ~95% of PKM mRNA expression.
2.2. The Prognostic Effect of PKM at the Transcript Level
We investigated the associations between the mRNA expression of PKM and its
seven highly expressed transcripts with the patients’ survival outcomes based on the
clinical survival metadata of patients in TCGA. We performed a Kaplan–Meier survival
analysis for the patients by classifying the patients into two groups with high and low
expression of the investigated transcript by optimally selecting a cutoff from the 10th
to 90th expression percentiles yielding the lowest log-rank p-value as in our previous
study [3] (Tables S3 and S4). As shown in Figure 2a, the mRNA expression of the PKM
indicated opposite survival outcomes in different cancer types. At the transcript level, we
found six of these transcripts, including PKM1, PKM2, PKM-609, PKM-093, PKM-883, and
ENST00000562997, are significantly associated with patients’ survival outcome in at least
one cancer. Among them, the mRNA expression of transcript encoding PKM2 exhibited a
very similar prognostic indication to PKM in all cancer types since it dominates the mRNA
expression of PKM (Table S2). Notably, we observed that the expression levels of transcript
encoding PKM1, which has been associated with different cancer types [22,23,40,41] is only
prognostic in HNSC.
High expression of PKM2, PKM-609, PKM-093, and PKM-883 indicated opposite clini-
cal survival outcome in different cancer types. This is exemplified by PKM-883, whose high
expression indicates unfavorable survival in KIRC patients and favorable survival in lung
squamous cell carcinoma (LUSC), prostate adenocarcinoma (PRAD), cervical squamous
cell carcinoma and endocervical adenocarcinoma (CESC), PAAD, pheochromocytoma and
paraganglioma (PCPG), breast invasive carcinoma (BRCA), and SKCM. We also found that
the expression of PKM indicated an opposite survival outcome of patients compared to that
of its transcripts in multiple cancer types. For example, PKM-883 exhibited the opposite
prognostic indication compared to PKM in KIRC, CESC, PAAD, and BRCA (Figure 2a).
Moreover, the high expression of different PKM transcripts may induce opposite prognoses
in patients with the same cancer. This is exemplified in KIRC, where high expression of
PKM2 and PKM-609 pair indicated favorable prognoses of patients and high expression of
PKM-093 and PKM-883 pair indicated the opposite, and similar scenarios could be found
in CESC, PAAD, BRCA, and colon carcinoma (COAD).
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Figure 1. Exon–intron structure of pyruvate kinase muscle type (PKM) transcripts and their corresponding expression 
levels in cancer and normal tissues. (a) Exon–intron structure of PKM transcripts. Blue color denotes translated region of 
exon. Orange color denotes intron. Black color denotes untranslated region of exon. Gray color denotes the missing se-
quence. (b) The expression levels of PKM transcripts in 25 human cancers from the Cancer Genome Atlas Program 
(TCGA). The transcripts per kilobase million (TPM) values were on log 2 scale. 
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Figure 1. Exon–intron structure of pyruvate kinase muscle type (PKM) transcripts and their corresponding expression levels
in cancer and normal tissues. (a) Exon–intron structure of PKM transcripts. Blue color denotes translated region of exon.
Orange color denotes intron. Black color denotes untranslated region of exon. Gray color denotes the missing sequence.
(b) The expression levels of PKM transcripts in 25 human cancers from the Cancer Genome Atlas Program (TCGA). The
transcripts per kilobase million (TPM) values were on log 2 scale.
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2.3. Potential Biological Functions Associated with PKM Transcripts
We identified four different transcripts of PKM including PKM2, PKM-609, PKM-
093, and PKM-883 which exhibited opposite prognostic effect in multiple cancer types.
Hence, we investigated whether this opposite trend is also observed at the functional
level in all cancer types. To systematically identify the functions of the four prognostic
PKM transcripts, we identified the differentially expressed genes (DEGs) between patients
with the top 25% high expression and bottom 25% low expression of each transcript in
all cancers (FDR < 1.0 × 10−5). We performed a gene ontology (GO) enrichment analysis
using the DEGs driven by each transcript, and summarized the results of the enriched GO
terms for all transcripts in all cancer types (FDR < 0.001, Figure 2b and Table S5). As shown
in Figure 2b, if a GO term is enriched with DEGs in multiple cancers, the directionality of
the DEGs often follows the same direction. For example, as shown in Figure 2b, the DEGs
identified by comparing high and low expression of PKM2 are enriched in extracellular
matrix organization pathway in 16 cancers and are always associated with the upregulated
genes. Our analysis indicated that although the prognostic effect of each transcript is
different, the associated biological functions are conserved in different cancers.
Next, we focused on GO terms that are consistently enriched in more than 10 cancers
and conservatively associated with the corresponding transcript. We investigated the en-
riched GO terms associated with PKM2. As shown in Figure 2b, glycolytic process, hypoxia
response, nicotinamide adenine dinucleotide hydride (NADH) regeneration pathways
are enriched with upregulated genes in patients with high expression of PKM2. This is
expected since it reflects the key enzymatic role in glycolysis of PKM2. On the other hand,
ATP synthesis, mitochondrial respiratory process, oxidative phosphorylation pathways
are enriched with downregulated genes, which probably indicates the shift from oxidative
phosphorylation to glycolysis that is well known as the Warburg effect in cancer. Moreover,
the upregulated genes were also enriched in pathways associated with the cell morphology
such as cell motility, cell migration, cell adhesion, and cell junction pathways. These
could be linked to the tumorigenesis role of PKM2 [11,24,25,42]. Interestingly, several
RNA processing related pathways, translational initiation pathways, and pathways related
to protein localization were also enriched with downregulated genes in cancer patients
with high expression of PKM2. These pathways were rarely associated with the biological
function of PKM in previous studies and appeared as commonly enriched GO terms in the
same analysis for three other transcripts. Hence, studying alternative splicing processes of
PKM in different cancers might provide further understanding about the potential role of
PKM in cancer progression.
Then, we investigated the function of three other transcripts of PKM whose functions
were not known. We found that many of the enriched GO terms associated with these
three transcripts are similar to the GO terms associated with PKM2 (Figure 2b). However,
the GO terms associated with the PKM-609 followed the same direction with those of
PKM2, of which followed the opposite direction with the GO terms associated with both
PKM-093and PKM-883. In total, 27 different GO terms, e.g., oxidative phosphorylation,
translational initiation, and RNA catabolic processes, are enriched with genes that are
downregulated with both PKM2 and PKM-609, and genes that are upregulated with both
PKM-093 and PKM-883.
We also compared the DEGs identified by comparing high and low expression of each
transcript and observed similar results based on the directionality and overlap of the DEGs.
For instance, in KIRC (Figure S1), we identified 3162 and 6592 DEGs (FDR < 1.0 × 10−5)
when comparing the high and low expression of PKM2 and PKM-609, respectively, which
both exhibited favorable prognostic indications. We found that the two sets of DEGs had
a significant overlap (n = 2010; hypergeometric distribution test, p < 1.11 × 10−16) and
the concordance score of these overlapped genes (using directionality of the DEGs) is
99.06%. We also identified 6541 and 6885 DEGs (FDR < 1.0 × 10−5) when comparing the
high and low expression of PKM-093 and PKM-883, respectively, which both exhibited
unfavorable prognostic effect in KIRC. Notably, we found that the overlap between the
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DEGs of the transcripts is 5469 (hypergeometric distribution test, p < 1.11 × 10−16) and the
concordance score of the overlapped genes is 100%. On the other hand, we investigated the
overlap between DEGs associated with the transcripts exhibiting the opposite prognostic
effect and found that there is no statistically significant overlap. For instance, in KIRC, the
concordance score of the overlapped DEGs between transcripts with opposite prognostic
indications were between 0.10% and 20% (Table S6 and Figure S1). Similar scenarios were
also observed in CESC, PAAD, BRCA, and COAD (Tables S7–S10). Our results suggested
that both PKM2 and PKM-609 have similar biological functions that are opposite to those
of PKM-883 and PKM-093.
2.4. Validation of the Prognostic Effect in Independent Kidney Renal Clear-Cell Carcinoma
(KIRC) Cohort
We performed a survival analysis for these four transcripts in 100 KIRC patients
involved in an independent Japanese study [43]. As shown in Figure 3a, the high expression
of both PKM2 and PKM-609 are significantly (log-rank p < 0.05) associated with the
favorable survival of patients whereas the high expression of PKM-093 and PKM-883 are
significantly associated with an unfavorable survival of patients. Our analysis indicated
that PKM2 and PKM-609 are favorable prognostic transcripts and PKM-093 and PKM-883
are unfavorable prognostic transcripts in KIRC and it was similar to the results based on
the TCGA KIRC cohort. Moreover, we employed univariate and multivariate Cox analysis
to evaluate the prognostic value of these four transcripts (Table S11). In the univariate
Cox analysis, all four transcripts exhibited significant association with patients’ overall
survival in the TCGA cohort. Moreover, after taking the PKM2 as a covariate, PKM-093 and
PKM-883 are still significantly prognostic in multivariate Cox analysis. Considering that
PKM-609 and PKM-883 are more closed to PKM1 rather than PKM2 in terms of nucleotide
sequence, we also took PKM1 as the covariate and performed multivariate Cox analysis.
Our result showed that all four transcripts still exhibited significant prognostic effect.
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Figure 2. Prognostic and functional analysis of PKM and its alternatively spliced transcripts in TCGA cancers. (a) Heat map
of the log-rank p-values (on the negative log 10 scale) of PKM and seven transcripts (average TPM > 5) in 25 cancer-types.
Six of these transcripts are significantly associated with patients’ survival outcome in at least one cancer. The Kaplan–Meier
plots for kidney renal clear-cell carcinoma (KIRC) was exemplified. Asterisk means log-rank test p < 0.05. (b) Bubble plot
showing the common enriched gene ontology (GO) terms among the 25 cancer-types in the TCGA. False discovery rate
(FDR) < 0.001 was used to identify the significantly enriched GO terms. Bubble sizes represent numbers of genes associated
to the biological function in a specific GO term; the x and y axes indicate the directions and generalities of the GO terms.
Generality is defined by the number of cancers with differentially expressed genes (DEGs) associated with each transcript;
direction is defined by the number of cancers with their upregulated genes over-representing the GO function minus the
number of cancers with downregulated genes over-representing the GO function. Note that only functions enriched with
more than 10 cancers are shown. The red bubbles denote the commonly detected GO terms enriched with upregulated
DEGs and the green bubbles denote the commonly detected GO terms enriched with downregulated DEGs.
To investigate whether these transcripts regulate the similar genes in two different
cohorts, we compared the DEGs by comparing the expression of each transcript in patients
with the top 25% high expression and bottom 25% low expression in Japanese and TCGA
KIRC cohorts. For fair comparison, we selected the top 20% of the DEGs (n = 2694) in TCGA
and Japanese cohorts and checked their overlap between genes. We found that the number
of overlapped DEGs identified for PKM-609, PKM-093, and PKM-883 are 1370, 1499, and
1449 (hypergeometric distribution test, p < 1.11 × 10−16) and the concordance scores of
the overlapped genes between the cohorts are 100%, 99.93%, and 99.86%, respectively
(Table S12). Our analysis indicated that the biological functions associated with each of
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these three transcripts are highly conserved in an independent KIRC cohort. However,
we found that the number of overlapping DEGs identified with the transcript PKM2 in
both cohorts is relatively small (n = 546; hypergeometric distribution test, p ≈ 1) and the
concordance score of the overlapped genes is 75.46%, which also indicates the differences
between the two cohorts. Such differences may be explained by the dietary and racial
differences between the two independent cohorts.
2.5. Combined Prognostic Signature for KIRC
Based on the highly conserved prognostic effects of the PKM transcripts in two
independent KIRC cohorts, there are likely to be different molecular subtypes among KIRC
patients with opposite expression patterns of the transcripts highlighted in this study. Thus,
we extracted a prognostic signature based on the expression value of these four transcripts
(see Method). In brief, if more than half of the transcripts indicate an unfavorable prognosis,
the patient is classified as high-risk and otherwise as low-risk. Using this rule, we observed
significantly different overall survival (log-rank p < 0.01) between high- and low-risk
groups in both TCGA and Japanese KIRC cohorts (Figure 3b).
To investigate whether these two molecular subtypes identified in both cohorts ex-
hibited similar biological differences, we extracted the top 20% most significant DEGs
(n = 2694) between high-risk and low-risk groups in the TCGA and Japanese cohorts. The
two lists of DEGs had significant overlap (n = 1516; hypergeometric distribution test,
p < 1.11 × 10−16) and the concordance score of the overlapped genes was 100%. In addi-
tion, we identified 57 and 74 GO terms that are significantly enriched with upregulated
genes (FDR < 1.0 × 10−5) in the high-risk group of the TCGA and Japanese cohorts, respec-
tively (Figure 3c, Table S13). Interestingly, we found that 55 of these enriched GO terms
are common in both cohorts and the molecular subtypes identified by our analysis have
consistent biological differences. Moreover, 26 of the 27 GO terms that are significantly
associated with the four transcripts (e.g., oxidative phosphorylation, translational initiation,
and RNA catabolic process) are also among the overlapped enriched GO terms (Figure 2b).
Our analysis indicated that the molecular subtypes are functionally related to the PKM2
and other three functional key transcripts of PKM identified in this study.
2.6. Discovery of the Protein Products of the Prognostic Transcripts
To investigate and compare the protein products of the three novel transcripts in-
cluding PKM-609, PKM-093, and PKM-883, whose functions were previously unknown
compared to the function of PKM2, we first aligned their amino acid (AA) sequences
(Table S14). We observed that PKM2 has the longest AA sequence with 531aa, followed
by the protein products of PKM-609, PKM-093, and PKM-883, which are 485aa, 457aa,
and 366aa, respectively. As shown in Figure 4a, we found that proteins of PKM-093 and
PKM-883 miss a part of the A1 and B domains (59-132aa and 41-205aa) in PKM2, which
may affect the formation of dimer [44]. We also found that the protein product of PKM-609
is shorter than PKM2, missing amino acid residues 486-531aa from PKM2 which is a part
of the C-domain participating in the formation of tetramer [44]. This implied that the
protein encoded by PKM-609 may have no tetrameric formation. In addition, there is part
of the AA sequence, 389-433aa, of the protein product of PKM-609 and PKM-883 resembles
PKM1 protein rather than PKM2. In this part, K433 is the FBP binding site in PKM2, which
activates the association of monomer to form the tetrameric [6]. However, PKM1 does not
bind FBP due to AA difference at the FBP binding pocket and it naturally exists as a stable
tetramer that has high constitutive activity [45]. In addition, all protein products of the three
transcripts have K270, which is the active site, binding to phosphoenolpyruvate (PEP).
Furthermore, we constructed the homology models of PKM-609, PKM-093, and PKM-
883 to obtain the protein structure information. When compared to the PKM2 structure, we
found that the PKM-093 structure is missing the catalytic site for adenosine diphosphate
(ADP) binding (59-132aa) and several AA residues, including R73, Q75, H78, G79, H80,
E118, and R120 from the missing part are in close contact with ADP (Figure S2). Instead, the
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PKM-093 structure forms a newly ordered loop going straight through the ADP binding
site, and whether this loop is able to coordinate the ADP binding is still unknown. On
the other hand, we observed that the PEP and the FBP binding site in PKM-093 structure
is fully maintained as in the PKM2 structure, and the tetramer binding interface is kept
the same as in PKM2 structure. The protein product of PKM-609 shares exactly the same
AA sequence as in PKM1, but misses the AAs from 486 to 531 in PKM1. By overlapping
the structure of the protein product of PKM-609 with PKM1, we found that the protein
maintains well defined ADP and PEP binding sites. However, the missing part constitutes
part of the C-C binding interface (Figure S2). Therefore, whether the PKM-609 functions as
a dimer or active tetramer needs further investigation. Comparing the protein of PKM-883
with PKM1, we observed that it misses a large part of both A and B domain as well as the
whole N-terminal part. This led to a loss of a large part in the ADP binding site and the
binding interface, whereas the PEP binding site in PKM-883 structure (Figure S2) was kept.
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The Kaplan–Meier plots for the samples classified by the high and low expression of transcripts including PKM2, PKM-609,
PKM-093, and PKM-883 in Japanese cohort. (b) The Kaplan–Meier plots for the samples classified by the prognostic
signature in TCGA and Japanese KIRC cohorts. (c) Network plot of enriched GO terms for DEGs between TCGA and
Japanese KIRC cohorts. Sizes of the nodes are correlated with the corresponding total number of genes, and connections
between the nodes indicate the significant overlaps (hypergeom tric dis ribution te t; FDR < 1.0 × 10−5) between the genes
of the corresponding GO terms. Nodes in red, blue, and urple indicate GO terms t at e riched in both cohorts, only
in Japanese KIRC cohort, and only in TCGA KIRC cohort, respectively. The nodes highlighted in dark red indicate the
common GO terms associated with all four transcripts reported in this study.
As we have shown that th AA sequence of th pr tein products of PKM-609, PKM-093,
and PKM-883 resemble different parts of either PKM1 r PKM2, it is difficult to stratify
them ba ed on the AA s quence only. However, we observed that all of these transcripts
have a different length of AA sequences, and different protein masses. The prot in masses
for PKM1 and PKM2 are 58.1 kDa and 57.9 kDa, respectively, while the mass for protein
products of PKM-609, PKM-093, and PKM-883 are 53.0 kDa, 49.9 kDa, and 40.2 kDa, re-
spectively. Therefore, we could separate these proteins based on their mass differences
using sodium dodecyl sulfate (SDS) gel electrophoresis and evaluated them by western
blot using one antibody that targeted their common sequence using a method developed
in a previous study [46]. We selected an antibody whose targeting sequence is between
the 243 to 531 AA of PKM2 to detect the other three transcripts, and as shown in Figure 4a
we predict this antibody should also be able to bind to the other three transcripts since
they share a large portion of AA sequence. As the expression of PKM-609, PKM-093, and
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PKM-883 are much lower than the expression of PKM2 and the antibody was not originally
designed to target these three variants, we expected that the bands of PKM-609, PKM-093,
and PKM-883 will have much less intensity. Thus, we used different exposure time and
gel cutting strategy to optimize the visualization of the different bands in order to help
to discover the predicted bands for PKM isoforms. As shown in Figure 4b, the band for
PKM1/2 is visualized via automatic exposure procedure for the full gel while the PKM-609,
PKM-093, and PKM-883 bands are obtained after gel cropping and the exposure time is
increased to 5 min to optimize the visualization. As we expected, we found that there are
different bands that appeared around 49 kDa and 40 kDa in the western blots (Figure 4c
and Figure S3) in the whole lysate of the three different human cell lines, which is in very
good agreement with the putative mass of protein products from PKM-093 and PKM-883,
respectively. We also quantified the relative protein level of protein products from PKM-093
and PKM-883 compared to PKM1/2 based on the uncropped western blots image of whole
lysate (Table S15) and found that they are similar to the relative mRNA level observed in
tumor samples from TCGA (Table S2). In addition, we also extracted the cytosolic and
nuclear protein to detect the two predicted isoforms by western blots (see Method section).
We observed the two bands in the same location in the western blots of the cytosolic and
nuclear proteins, which implies these two proteins could potentially play regulatory roles
in cell nucleus as PKM2.
Although we observed the bands that potentially represent the protein products of
PKM-093 and PKM-883, there is still a chance that these bands are shown because of the
non-specific binding of the antibody. To further validate whether the bands we identified
are encoded by PKM-093 and PKM-883, we used three different siRNAs to inhibit the
expression all protein isoforms of PKM. As shown in Figure 4d and Figure S4, the cellular
PKM level is decreased with the siRNA transferred to the cells. In addition, we found
the bands located at 49 kDa and 40 kDa also significantly decreased. This indicated that
the two bands we identified are encoded by PKM. Moreover, we manually cut the gel
with protein in PC3 from 37 kDa to 50 kDa based on the marker and separated it into
three horizontal slices. Subsequently, we subjected the samples to enzymatic digestion
and extracted peptides for analysis in mass spectrometry (MS). Consequently, we detected
signals of peptides from PKM-093 and PKM-883 on both the top (49.9 kDa) and bottom
(40.2 kDa) slices (Table S16). As shown in Figure 4e, both of these slices showed high MS
intensity with good peptide coverage, proving that the bands we identified are related
to the corresponding transcripts. With respect to the one from PKM-609, we could not
visually separate the bands from PKM1 and PKM2 since it had a similar mass compared to
PKM1 and PKM2.




Figure 4. Protein products of the functional alternatively spliced PKM transcripts. (a) Alignment of amino acid sequence 
of the four functional different transcripts and the transcript encoding PKM1. The gray color denotes missing part com-
pared to PKM2. The yellow color denotes a subsequence that is specific to PKM1. (b) Schematic diagram showing the 
different exposure time and gel cutting strategy to optimize the visualization of the different bands of PKM isoforms. The 
band for PKM1/2 is visualized via automatic exposure time in the full gel while the PKM-093 and PKM-883 bands are 
obtained after gel cropping and the exposure time is increased to 5 min to optimize the visualization. (c) Western blots for 
the proteins encoded by the transcript PKM-093 and PKM-883 in cytosol and nucleus with the same protein mass (see 
Method section). The red dot means cytosolic protein and the green dot means nuclear protein. (d) Western blots showing 
the protein level of PKM1/2 and protein products of PKM-093 and PKM-883 with siRNA and negative control. The expo-
sure time and gel cutting strategy is same as (c). (e) Peptides detected using MS aligned with amino-acid sequence of 
respective transcript products on the x-axis and intensity on the y-axis. 
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2.7. Exploring the Biological Function of the Prognostic Transcripts
In order to explore the function of the prognostic transcripts identified in this study,
we designed vectors and transfected to PC3 cancer cell lines to over-express PKM-093
and PKM-883. We excluded PKM-609 since the stop codon is missing in the genome
annotation. As shown in Figure 5a and Figure S5, we observed that the protein levels of
PKM-093 and PKM-883 were elevated compared to negative control, which proved that
the transfection is successful as expected. We did not observe any significant changes
in cell viability after the over-expression of the transcripts (Figure S6). To test whether
over-expression of the transcripts increases the pyruvate kinase activity, we extracted the
cell lysate from PC3 cell lines with empty vector, PKM-093 over-expression, and PKM-883
over-expression and found that the enzymatic activity is significantly increased in cell
lysate with the overexpressed transcripts compared to negative control (Figure 5b). We
also repeated the same experimental procedure using U2OS cancer cell lines and obtained
similar results (Figure S7). Moreover, we used another vector to overexpress PKM-093
and PKM-883 with no tag, HA tag at the C-terminal, and FLAG tag at the N-terminal, and
respectively evaluated the pyruvate kinase activities in their cell lysates. Interestingly, we
observed that overexpressed PKM-093 and PKM-883 with no tag and tag at the N-terminal
but not C-terminal could elevate the pyruvate kinase activity in the cell lysate (Figure S8).
This suggested that the tag in the C-terminal changed the C-C interface structure, thus
disturbing the formation of tetramer which is the enzymatically more activated form
compared to dimer. This strongly indicated that the PKM-093 and PKM-883 are functional
and protein products of these transcripts possess the pyruvate kinase activity.
To assess the relative abundance of PKM-093 and PKM-883 in cell cytosol and nucleus,
we overexpressed these two proteins and extracted cytosolic and nucleic protein from the
same cell portion in order to compare their abundance by western blot using PKM antibody.
Surprisingly, we observed that the majority of the overexpressed PKM-093 and PKM-883
proteins are mainly located in the nucleus, which is the opposite compared to PKM1/2
(Figure 5c and Figure S9). This suggests that PKM-093 and PKM-883 may have different
functional purposes compared to PKM1/2 and play important regulatory roles. In addition,
we evaluated the effect of over-expression on cell invasion using an experimental assay. As
shown in Figure 5d, we observed that the cells with PKM-093 over-expression exhibited
significantly inhibited invasion (~30% decrease compared to negative control), while the
over-expression of PKM-883 had no significant effect on cell invasion of PC3 which is a
PRAD cell line. This is in good agreement with what we observed for PKM-093 since cell
migration has been negatively associated with PKM-093 in differential expression analysis
in PRAD patients. To further investigate the functional role of these two transcripts, we
quantified the mRNA expression of several important marker genes in negative control,
PKM-093 and PKM-883 overexpressed PC3 cancer cell lines using qPCR (Figure 5e). We
found that the over-expression of both transcripts significantly increased the expression of
GLUT-1 (SLC2A1), which is the main glucose transporter. Our results indicated that these
two transcripts may play important roles in glucose metabolism as we expected. PDK1 is
an important gene in hypoxia and it has been reported to be associated with the abnormal
expression of PKM2 and Warburg effect [47]. We also observed that the expression of
PDK1 has been significantly elevated with over-expression of PKM-883. The change of
PDK1 indicated a potential role of PKM-883 in hypoxia response. SREBF1 is a well-known
transcription factor that regulates fatty acid metabolism, and it has been reported that the
downregulation of PKM2 reduced the expression of SREBF1 in cancer cells [48]. In our
analysis, SREBF1 is also significantly increased with PKM-883 over-expression, suggesting
PKM-883 has potential regulatory function in fatty acid metabolism. Based on these results,
we concluded that protein products of both PKM-093 and PKM-883 possess pyruvate
kinase activity in different cancer cell lines and these transcripts may have a major role in
biological functions associated with cancer progression.
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volume (see Method Section 4.7). The red dot means cytosolic protein and the green dot means nuclear protein. (d) Bar 
chart and microscopy images showing the over-expression of PKM-093 and PKM-883 significantly inhibited cell invasion 
compared to negative control. Error bars indicate standard errors. * indicates t-test p < 0.05. Scale bar = 100 micrometer 
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Figure 5. Biological effect of PKM transcript over-expression in PC3 human prostate cancer cell line. (a) Western blots image
showing the over-expression of transfected PKM-093 and PKM-883, respectively. (b) Pyruvate kinase activity kinetic assay.
Kinetic PK activity was measured using 7.5 µg of each transfected cell lysate. PKM-093 and PKM-883 reached faster plateau
status at 6 and 8 min, respectively, than pCMV6KN empty vector control which reached plateau at 10 min. (c) Western blots
for the overexpressed proteins of PKM-093 and PKM-883 in cytosol and nucleus with the same protein volume (see Method
Section 4.7). The red dot means cytosolic protein and the green dot mea s nuclear protein. (d) Bar chart and microsc py
images showi g the over-expression of PKM-093 and PKM-883 significantly inhibi ed cell invasion compared to negative
control. Error bars indicate standard errors. * indicates t-test p < 0.05. Scale bar = 100 micrometer (µm). (e) Quantitative
PCR analysis showing the mRNA level changes of SLC2A1, PDK1, and SREBF1 in PC3 cells with PKM-093 and PKM-883
over-expression compared to negative control. Error bars indicate standard errors. * indicates t-test p < 0.05.
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3. Discussion
Protein isoforms produced by alternative splicing of the same gene contribute to
proteome complexity and modulate the patterns of gene expression that govern many
cell fate decisions [49]. There are seven basic alternative splicing events including exon
skipping, mutually exclusive exons, alternate acceptor sites, alternate donor sites, alternate
promoter, alternate terminator, and retained intron. Previous studies have already detected
the survival-associated alternative splicing events or differentially splicing events involved
in specific exons as the prognostic biomarker or drug response biomarker in different
human cancers [50–53]. It has also been reported that the different alternative splicing
events occurring in the same gene show opposite prognostic effects in the same cancer
type [50,51], suggesting that these protein isoforms may have diverse or even opposite
biological functions [54]. In this study, we only focus on the expression of different al-
ternatively spliced transcripts of PKM and explore the potential biology functions and
prognostic effects in different cancers. Several studies have been performed for studying
the functional role of PKM in cancer metabolism, mainly focusing on PKM1 and PKM2
isoforms. With the development of bioinformatics tools for the analysis of the RNA-seq
data like Kallisto [55], it is now possible to quantify the isoforms and perform systematic
studies for revealing the functional role of transcripts in cancer progression. Here, we
performed a transcript level analysis of PKM and found that four of them, including PKM2,
PKM-609, PKM-093, and PKM-883, could play a key role in KIRC progression. We found
that mRNA expression of these four transcripts exhibited opposite survival correlation.
For example, the over-expression of PKM2 and PKM-609 indicates the favorable survival
outcome for KIRC patients while the over-expression of PKM-093 and PKM-883 indicates
unfavorable survival outcome. In contrast, the prognostic effect of PKM2 compared with
PKM-093 and PKM-883 are reversed in CESC, PAAD, and BRCA. Moreover, we found that
these isoforms of PKM potentially regulate the same set of biology functions with opposite
regulatory directions based on the systems biology analysis. These results might explain
the controversial prognostic indication of PKM in different cancers reported previously.
Next, we validated their prognostic effect in an independent KIRC cohort, which provides
additional confidence of our prognostic finding. To further support our bioinformatic
prediction, we characterized for the first time the protein products of these key transcripts
using western blots and mass spectrometry-based proteomics analysis and demonstrated
that these proteins possess pyruvate kinase enzyme activity and could potentially play
important roles in glucose and lipid metabolism, invasion, and hypoxia.
Previous studies reported that the ratio between PKM1 and PKM2 isoforms plays
a key role in cancer progression [56–60]. In our study, we found PKM1 is not strongly
associated with the survival of cancer patients as has been reported [34]. Based on our
analysis, we observed that the disagreement between the studies may be explained by the
differences in transcriptomic quantification methods used in the analysis of the data. For
instance, a recent study quantified the mRNA level of PKM1 and PKM2 using RT-PCR
and reported their association in cancer [61], but the primer they have used for RT-PCR
could also bind to PKM-883 and PKM-609. Thus, the RNA level suggested for PKM1
transcript also includes other PKM transcripts rather than just PKM1. In addition, we also
found that the RNA level of PKM1 (<5%) is very low compared to PKM2 (~95%) which is
in good agreement with proteomics data reported earlier [62], and it has the same order
of magnitude as PKM-883 and PKM-609 (Table S2). In this context, it is very likely that
PKM-883 or PKM-609, which showed prognostic effect in our study, may also play a key
role in tumor metabolism.
We also showed the protein products of these two transcripts using western blots
and validated their presence by MS after the identification of functional alternatively
spliced PKM transcripts. It is quite difficult to distinguish these transcripts and PKM2
since they shared the majority of their nucleotide and AA sequences. For instance, the
antibody we used in this study is designed to specifically target the PKM2 protein, but
it also bound the protein products of PKM-883 and PKM-093. Therefore, this might be a
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potential explanation for the contradicting prognostic effect related to PKM2 in different
studies, and there may be a need to revisit some of the previous studies to investigate all
isoforms of PKM.
4. Materials and Methods
4.1. Data and Preprocessing
The TCGA transcript-expression level profiles (TPM and count values) of 25 cancer
types with more than 100 patients—excluding low grade glioma (LGG) for the same rea-
son as in our previous study [3]—were downloaded from https://osf.io/gqrz9 [63] on
27 November 2018. We only extracted the tumor samples with sample identifier of BRC
patient barcode ‘01′ for solid tumor and ‘03′ for acute myeloid leukemia, respectively, and
with the vial identifier “A” for all the tumor types. We quantified the mRNA expression
using Kallisto [55] based on the GENCODE reference transcriptome (version 24) (Ensembl
83 (GRCh38.P5)). The clinical information of TCGA samples was downloaded through
R package TCGAbiolinks [64]. The whole-exome sequences data of 100 KIRC samples
of patients from Japanese cohort [43] were download from European Genome-phenome
Archive (accession number: EGAS00001000509). BEDTools [65] was used for converting
BAM to FASTQ file. Kallisto was used for estimating the count and TPM values of tran-
scripts based on the same reference transcriptome of TCGA data. The sum value of the
multiple transcripts of a gene was used as the expression value of this gene. The genes
with average TPM values >1 across patients in each cancer were analyzed.
4.2. Survival Analysis
Based on the TPM value of each transcript or gene, we classified the patients into
two groups and examined their prognoses. Survival curves were estimated by the Kaplan–
Meier method and compared by log-rank test. To choose the best TPM cutoffs for grouping
the patients most significantly, all TPM values from the 10th to 90th percentiles used to
group the patients, significant differences in the survival outcomes of the two groups were
examined and the value yielding the lowest log-rank p-value was selected. The R package
survival and graphics were used for survival analysis and plotting survival curves.
For retrieving prognostic signature, we used the expression cutoff obtained in the
individual survival analysis for each of the four transcripts which could classify the patients
into two groups with significantly different prognoses. In TCGA cohort, if the expression
of PKM2 or ENST00000561609 was less than 476.35 or 0.69 in a sample, this sample was
classified into high-risk group, otherwise, low-risk group. On the other hand, if the
expression value of ENST00000389093 or ENST00000568883 was higher than 18.18 or 13.74
in a sample, this sample was classified into high-risk group, otherwise, low-risk group.
Similarly, the cutoffs of the four transcripts were 815.84, 0.33, 7.90, and 6.63 in the Japanese
cohort. Therefore, we classified the samples of the two different cohorts into the high-risk
group when at least two transcripts were higher or lower than the corresponding cutoffs.
Moreover, univariate and multivariate Cox analyses were performed to confirm the
prognostic values of these four transcripts based on R package ‘survival’. We took the
expression of PKM1/2 as a covariate when we evaluated the prognostic values of the other
transcripts in multivariate Cox analysis because of the sequence similarity.
4.3. Differential Expression Analysis
DESeq2 [66] was used to identify differentially expressed genes (DEGs) between two
groups. Before performing DESeq2, we removed the low expressed genes with average
TPM ≤ 1 and then we used the raw count values of the rest genes as the input of DESeq2.
The Benjamini–Hochberg procedure was used to estimate FDR. FDR < 1.0 × 10−5 was used
to identify significant DEGs.
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4.4. Overlapping of Two Lists of Differentially Expressed Genes DEGs
If DEG list 1 with L1 genes and DEG list 2 with L2 genes have k overlapping genes,
among which s genes shows the same directions (up- or down-regulation) in the two DEGs
lists, the probability of observing at least s consistent genes by chance can be calculated
















where L represents the number of the background genes commonly detected in the datasets
from which the DEGs are extracted. The two DEG lists were considered to be significantly
overlapped if p < 0.05.
The concordance score s/k is used to evaluate the consistency of DEGs between the
two lists. Obviously, the score ranges from 0 to 1, and the higher concordance score
suggested the better consistency of two lists of DEGs.
4.5. Functional Enrichment Analysis
Gene ontology (GO) enrichment was performed by the enrichGo function in R package
ClusterProfiler [67], in which the hypergeometric distribution was used to calculate the
statistical significance of biological pathways enriched with DEGs of interest.
4.6. Hierarchical Clustering
Log-rank p-values were hierarchically clustered by Spearman correlation distance
and Ward linkage method (ward.D2). Negative log 10 transformation of p-values was
performed before clustering.
4.7. Western Blots
Whole cell lysate was extracted with CelLytic M (C2978, Sigma-Aldrich, Saint Louis,
MO, USA) lysis buffer. Cytosolic and nucleus protein was extracted with Nuclear Ex-
traction Kit (ab113474, abcam, Cambridge, UK). Three million cells were counted and
collected. Fifty micrograms of whole lysate, cytosolic and nucleus protein were used to
detect endogenous ENST00000389093 and ENST00000568883. Proteins were separated
by Mini-PROTEAN® TGX™ Precast Gels (Bio-Rad, Berkeley, CA, USA) and transferred
using Trans-Blot® Turbo™ Transfer System (Bio-Rad, Berkeley, CA, USA). PKM2 anti-
body (ab137791, abcam) was used for primary antibody overnight. Goat Anti-Rabbit HRP
(ab205718) was blotted for one hour. PKM band were detected with ImageQuanattm LAS
500 (29-0050-63, GE) automatic exposure procedure and two PKM isotype band (49.9 kDa
and 40.2 kDa) were detected for 5 min exposure. Band intensity was measured via Im-
ageJ program. Overexpressed ENST00000389093 and ENST00000568883 localization was
observed by western blot analysis. Cytosolic and nucleus protein lysate were prepared
with Nuclear Extraction kit (ab113474). After cytosolic lysate extraction with 80 µL pre-
extraction buffer, insoluble nucleus had been washed with 150 µL of pre-extraction buffer
and extracted whole nuclear lysate with 80 µL of ENE2 (ab113474) nuclear extraction buffer
with sonication (Diagenode Bioruptor 300). Sonication was performed as 30 s sonication,
30 s rest for 20 cycles at high frequency. Five microliters of the same volume cytosolic and
nucleus lysate were loaded and analyzed with western blot. PKM2 antibody (ab137791,
abcam) Lamin B1 (ab16048) beta-actin (ab8227) antibody were blotted for 1.5 h. Goat Anti-
Rabbit HRP secondary antibody was blotted for 1 h. Cytosolic and nucleus FLAG tagged
ENST00000389093 and ENST00000568883 were detected in the same transfer membrane
with ImageQuanattm LAS 500 1-min exposure.
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4.8. Cell Culture and siRNA Transfection
All cells were cultured followed by ATCC instruction. PC3 cell culture media formulation
is F12K Nutrient mix supplemented with 10% FBS and 1% Penicillin/Streptomycin. U2OS
cells were cultured with McCoy’s 5A Medium with 10% FBS and 1% Penicillin/Streptomycin,
MRC5 cells were cultured with DMEM with 10% FBS and 1% Penicillin/Streptomycin, and
RWPE-1 cells were cultured with Keratinocyte Serum Free Medium (K-SFM) supplemented
with Bovine Pituitary Extract (BPE) and human recombinant Epidermal Growth Factor
(EGF) (Kit Catalog Number 17005-042). For siRNA treatment, 400,000 cells were seeded to
six-well plate. After 24 h of cell seeding 25 pmol siRNA was transfected by Lipofectamine®
RNAiMAX (13778-075 Invitrogen) for two days. pCMV6KN empty vector from ORIGENE
and pcDNA3.1(+) empty vector from GeneScript were used to clone ENST00000389093
and ENST00000568883 transcripts. Three hundred thousand cells of PC3 were seeded to
a six-well plate and FuGENE® HD (E2311 Promega) was used to transfect cloned vector
as 1:3 (3 µg of DNA, 9 µL of FuGENE®). After two-days transfection, culture media were
changed to the fresh media. RNA and protein lysate were harvested at the third day.
4.9. Sample Preparation for Mass Spectrometry Analysis
The gel pieces were subjected to in-gel digestion as described in previous study [68],
with some adjustments. Reduction was performed by addition of 10 mM dithiothreitol
and incubation at 56 ◦C for 30 min. The samples were alkylated by addition of 55 mM
2-chloroacetamide and incubation shielded from light for 20 min at room temperature.
Tryptic digestion was performed overnight at 37 ◦C after addition of trypsin solution
containing 13 ng/µL proteomics grade porcine trypsin (Sigma Aldrich, St Louis, MO, USA),
100 mM ammonium bicarbonate, 10% acetonitrile (ACN). The peptides were then extracted
by addition of 100 µL extraction buffer to each sample (1:2, 5% formic acid (FA)/ACN). The
extracted peptides were transferred to HPLC-vials and dried using vacuum centrifugation.
The peptides were then resuspended in 60 µL 3% ACN, 0.1% FA and analyzed by liquid
chromatography (LC)-MS/MS.
4.10. MS Analysis
PC3 cell lysate was prepared with CelLytic M (C2978, Sigma-Aldrich) lysis buffer. SDS
PAGE separated 60 µg of PC3 cell lysate per well with Precision Plus Protein Standards
ladder (1610374, Bio-Rad). Gel pieces were cut by razor blade, three pieces between 37 and
50 kDa ladder indicated.
The samples were analyzed using a Thermo Scientific Q Exactive HF (Thermo Fisher
Scientific, Waltham, MA, USA) online connected to a Dionex Ultimate 3000 UHPLC-system
(Thermo Fisher Scientific) equipped with a reverse phase trap column (Acclaim PepMap
100, 75 µm × 2 cm, 3 µm, 100 Å; Thermo Fisher Scientific) and 50 cm analytical column
(EASY-Spray, 75 µm × 50 cm, 2 µm, 100 Å; Thermo Fisher Scientific). Ten microliters of
each sample was injected for analysis and the peptides were separated over an 85 min
run using a 60 min linear LC-gradient and sprayed directly into the mass spectrometer
using the EASY-Spray ion source. The solvents used for the LC-gradient were 3% ACN,
0.1% FA (solvent A) and 95% ACN, 0.1% FA (solvent B). The flow rate of the system was
set to 300 nL/min and the gradient used was as follows: 5% solvent B for 3 min, 5–35%
solvent B within 60 min, 35–90% solvent B within 5 min, 90% solvent B for 7 min, 90–5%
solvent B within 0.1 min, 5% solvent B for 10 min. The mass spectrometer was set to operate
using a Top10 MS method with a full scan resolution of 60,000 (mass range: 400–1200 m/z,
AGC: 3 × 106) and a MS/MS resolution of 30,000 (AGC: 1 × 105). The normalized collision
energy was set to 30.
4.11. Data Analysis of MS Results
The raw files obtained from the MS experiment were analyzed using MaxQuant
(version 1.6.1.0) [69] implementing Andromeda [70] to search the MS/MS data against the
Ensembl Homo sapiens database (version 83.38, all protein coding transcripts from the
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primary assembly) as well as a separate database with the two distinct target sequences
(ENST00000389093 and ENST00000568883) a list of common contaminants. Trypsin/P was
used for cleavage specificity with up to two missed cleavages. Oxidation (M) was used as
a variable modification while carbamidomethylation (C) was used as a fixed modification.
The peptide and protein FDR were set to 1% and the minimum peptide length was set
to seven amino acids. The presence of the target proteins was assessed by evaluating the
identification of unique peptides specific to the proteins in the different samples.
4.12. Homology Model
The homology models were built using StructurePrediction panel in Schrödinger Suite
(Schrödinger, LLC., New York, NY, USA). The ClustralW method was used to align the
target and template sequences in Prime, the energy-based was selected for model building
method, and homo-multimer was selected for multi-template model type. The homology
model of ENST00000561609 was built based on the PKM2 crystal structure (PDB ID: 5X1W),
as ENST00000561609 shares 96% sequence similarity to PKM2, compared to 91% to PKM1.
ENST00000389093 and ENST00000568883 share higher sequence similarity to PKM1, with
100% and 92% correspondingly. These two homology models were built based on the
PKM1 crystal structure (PDB ID: 3SRF).
4.13. Quantitative PCR (qPCR) Analysis of SLC2A1, PDK1, SREBF1, SNAI2, FN1, and
CASP7 Expression
Cloned vector transfected PC3 cells were prepared as biological and technical triplicate.
RNA was isolated using TRIzol® Reagent (15596018, Life Technologies Carlsbad, Carlsbad,
CA, USA), and RNeasy® Plus Mini Kit (74136 Qiagen, Hilden, Germany) following the
manufacturer’s instructions. One microgram of total RNA was reverse transcribed into
cDNA using GoScriptTM Reverse Transcription System (A5001, Promega, Madison, WI,
USA) with manufacturer’s guidelines. CFX ConnectTM Real-Time System (Bio-Rad, Her-
cules, CA, USA) used to measure transcript level of target genes. iQ SYBR® Green Supermix
(1708882, Bio-Rad) was used to PCR mixture. Just 0.5 µL of cDNA and 1 µL of 100 nM
each primer was mixed to 20 µL total mixture. qPCR program has consisted of 45 cycles of
denaturation for 10 s at 95 ◦C, elongation, and detection for 30 s at 60 ◦C. When that final
cycle completed, melting curve analysis was performed within range of 55–95 ◦C (10 s,
0.5 ◦C). Final mRNA expression was calculated as average CQ value of biological and tech-
nical triplicates. Primer sequences are Beta actin: CACCAACTGGGACGACAT (Forward)
and ACAGCCTGGATAGCAACG (Reverse), SLC2A1: CCACTGCAACGGCTTAGACTT
(Forward) and TGGGTAACAGGGATCAAACAGA (Reverse), PDK1: CCTGGACTTCG-
GATCAGTGA (Forward) and TGCCGCAGAAACATAAATGA (Reverse), SREBF1: GCTC-
CTCCATCAATGACAAAATC (Forward) and TGCAGAAAGCGAATGTAGTCGAT (Re-
verse), SNAI2: AGCTACCCAATGGCCTCTCT (Forward) and TCACTCGCCCCAAA-
GATG (Reverse), FN1: CCAAGAAGGGCTCGTGTGA (Forward) and GGCTGGAACG-
GCATCAAC (Reverse), CASP7: GCCTGGGTTTTGACGTGATT (Forward) and CAGGCG-
GCATTTGTATGGT (Reverse).
4.14. Pyruvate Kinase Activity Assay
Whole cell lysate was prepared with lysis buffer (C2978, Sigma-Aldrich). Three
micrograms of PC3 cell whole lysate was used for pyruvate kinase assay (ab83432, abcam)
following manufacturer’s instruction. Kinetic measurement at O.D 570 nm by microplate
reader (Hidex Sense Beta Plus) recorded pyruvate kinase activity every minute for 40 min.
4.15. Invasion Assay
Cloned vectors were transfected to 300,000 cells of PC3. Day 2 transfection, trypsinize
cells and seed 200,000 cells to collagen coated 8 µm pore trans-well insert (3422, CORNING)
with serum free media. Trans-well placed to 600 µL of growth media in 24-well plate, then
growth factors in growth media induced invasion to bottom. After 24-h, trans-wells were
washed with PBS and stained by 0.2% crystal violet solution. PBS immersed cotton swab
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removed PC3 cells not invaded on upper well. Six images for invaded cells were taken
from middle, left, right, top, bottom, and right top of bottom side of trans-well. Stained
cells were counted and plotted as histogram.
5. Conclusions
We discovered the potential functional and prognostic roles of the three alternatively
spliced PKM transcripts in KIRC and different cancers based on systems biology analysis,
and partly validated them with in vitro experiments. Our study could serve as a primer for
future studies focusing on revealing the biological and oncological role of these alternative
spliced variants of PKM.
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